There is an unmet need for renoprotective drugs for more pronounced reduction of
albuminuria beyond that provided by renin-angiotensin system (RAS) blockers and for …

Dipeptidyl peptidase IV (DPPIV) is a widely expressed multifunctional serine peptidase that
exists as a membrane-anchored cell surface protein or in a soluble form in the plasma and …

Diabetic nephropathy is the principal cause of end-stage renal failure and current
interventions for its recession remains unsatisfactory. Mesenchymal stem cells (MSCs) hold …

Cytokines, such as transforming growth factor (TGF)-ß1, and increased oxidative stress are
considered to be responsible for the development of diabetic nephropathy. We hypothesized …

The poly (ethylene glycol)-b-brush poly (l-lysine) polymer (PEG-b-(PELG50-g-PLL3)) was
synthesized and evaluated as a nanocarrier for prolonging delivery of exenatide through the …

Aims Diabetic nephropathy, a major threat to diabetic patients, is considered as the main
reason for end-stage renal disease. Fortunately, incretin-based therapy has been aroused …

Аналоги глюкагоноподобного пептида-1 (ГПП-1) и ингибиторы дипептидилпептидазы 4
типа (ДПП-4) новые классы сахароснижающих препаратов с многочисленными …

Diabetes mellitus is the most prevalent metabolic disorder worldwide. Glycemic control is the
main focus of antidiabetic therapy. However, there are data suggesting that some …

Abstract Glucagon like peptide-1 (GLP-1) analogues and dipeptidyl peptidase-4 (DPP-4)
inhibitors are new classes of hypoglycemic agents with numerous pleiotropic effects. The …

In this study, we investigated the effect of exenatide (EXE), a glucagon-like peptide (GLP)-1
receptor agonist, on kidney function, obesity indices, and glucose control in …